Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low Risk Myelodysplastic Syndrome”

243 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 243 results

Testing effectiveness (Phase 2)Study completedNCT00940602
What this trial is testing

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 225
Early research (Phase 1)Ended earlyNCT04810611
What this trial is testing

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 33
Testing effectiveness (Phase 2)Ended earlyNCT00740181
What this trial is testing

Decitabine, Cytarabine, GCSF for Refractory AML/MDS

Who this might be right for
MyelodysplasiaLeukemia
Brown University 9
Testing effectiveness (Phase 2)Study completedNCT01338337
What this trial is testing

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia

Who this might be right for
Myelodysplastic Syndrome (MDS)
Asociación Andaluza de Hematología y Hemoterapia 40
Testing effectiveness (Phase 2)Study completedNCT04477850
What this trial is testing

Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Who this might be right for
Myelodysplastic Syndromes
Celgene 30
Not applicableStudy completedNCT04036448
What this trial is testing

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

Who this might be right for
Myelodysplastic SyndromesLymphoma, Mantle-CellLymphoma, Follicular
Celgene 28
Testing effectiveness (Phase 2)Study completedNCT03900715
What this trial is testing

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Who this might be right for
Myelodysplastic Syndromes
Celgene 21
Testing effectiveness (Phase 2)Study completedNCT01772420
What this trial is testing

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Who this might be right for
Adult Myelodysplastic SyndromeAnemiaChronic Myelomonocytic Leukemia
Albert Einstein College of Medicine 52
Testing effectiveness (Phase 2)Temporarily pausedNCT06630221
What this trial is testing

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

Who this might be right for
Myelodysplastic SyndromesChronic Myelomonocytic Leukemia
Abhay Singh, MD MPH 25
Testing effectiveness (Phase 2)WithdrawnNCT01302106
What this trial is testing

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Testing effectiveness (Phase 2)Ended earlyNCT01034657
What this trial is testing

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 34
Not applicableStudy completedNCT00856388
What this trial is testing

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in Remission+97 more
Roswell Park Cancer Institute 62
Testing effectiveness (Phase 2)Looking for participantsNCT04419649
What this trial is testing

Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesCytopenia
Takeda 160
Testing effectiveness (Phase 2)Study completedNCT00074074
What this trial is testing

Infliximab in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC 46
Large-scale testing (Phase 3)UnknownNCT00234143
What this trial is testing

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes
St. Bartholomew's Hospital 360
Not applicableStudy completedNCT00005799
What this trial is testing

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+42 more
Fred Hutchinson Cancer Center 55
Testing effectiveness (Phase 2)Study completedNCT00451997
What this trial is testing

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Who this might be right for
Leukemia, MyeloidMyelodysplastic Syndromes
M.D. Anderson Cancer Center 10
Large-scale testing (Phase 3)Ended earlyNCT00695396
What this trial is testing

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Who this might be right for
Myelodysplastic SyndromesAnemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 25
Testing effectiveness (Phase 2)Study completedNCT00397813
What this trial is testing

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Who this might be right for
Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Myelomonocytic Leukemiade Novo Myelodysplastic Syndrome+11 more
Fred Hutchinson Cancer Center 77
Large-scale testing (Phase 3)Study completedNCT02008318
What this trial is testing

Galunisertib in Participants With Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Eli Lilly and Company 43
Next Page